regulatory status comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Div. 1: Single early – with cup-shaped single flowers, no larger than 8 cm (3 inches) across. They bloom early to mid-season. Growing 15 to 45 cm (6 to 18 inches) tall. Div. 2: Double early – with fully double flowers, bowl shaped to 8 cm (3 inches) across. Plants typically grow from 30–40 cm (12–16 inches) tall. Div. 3: Triumph – single, cup shaped flowers up to 6 cm (2.5 inches) wide. Plants grow 35–60 cm (14–24 inches) tall and bloom mid to late season. Div. 4: Darwin hybrid – single flowers are ovoid in shape and up to 6 cm (2.5 inches) wide. Plants grow 50–70 cm (20–28 inches) tall and bloom mid to late season. This group should not be confused with older Darwin tulips, which belong in the Single Late Group below. Div. 5: Single late – cup or goblet-shaped flowers up to 8 cm (3 inches) wide, some plants produce multi-flowering stems. Plants grow 45–75 cm (18–30 inches) tall and bloom late season. Div. 6: Lily-flowered – the flowers possess a distinct narrow 'waist' with pointed and reflexed petals. Previously included with the old Darwins, only became a group in their own right in 1958. Div. 7: Fringed (Crispa) – cup or goblet-shaped blossoms edged with spiked or crystal-like fringes, sometimes called "tulips for touch" because of the temptation to "test" the fringes to see if they are real or made of glass. Perennials with a tendency to naturalise in woodland areas, growing 45–65 cm (18–26 inches) tall and blooming in late season. Div. 8: Viridiflora Div. 9: Rembrandt Div. 10: Parrot Div. 11: Double late – Large, heavy blooms.
==== Multiple bodies per grave ==== Some couples or groups of people (such as a married couple or other family members) may wish to be buried in the same plot. In some cases, the coffins (or urns) may simply be buried side by side. In others, one casket may be interred above another. If this is planned for in advance, the first casket may be buried more deeply than is the usual practice so that the second casket may be placed over it without disturbing the first. In many states in Australia all graves are designated two or three depth (depending on the water table) for multiple burials, at the discretion of the burial rights holder, with each new interment atop the previous coffin separated by a thin layer of earth. As such all graves are dug to greater depth for the initial burial than the traditional six feet to facilitate this practice. Mass burial is the practice of burying multiple bodies in one location. Civilizations attempting genocide often employ mass burial for victims. However, mass burial may in many cases be the only practical means of dealing with an overwhelming number of human remains, such as those resulting from a natural disaster, an act of terrorism, an epidemic, or an accident. This practice has become less common in the developed world with the advent of genetic testing, but even in the 21st century remains which are unidentifiable by current methods may be buried in a mass grave. Individuals who are buried at the expense of the local authorities and buried in potter's fields may be buried in mass graves.
== Saudi Arabia == Panda Carrefour HyperPanda Abdullah Al-Othaim Markets Tamimi Danube Al-Sadhan Supermarket Lulu Hypermarket Lulu Supermarket Nesto Hypermarket BinDawood Farm Superstores Sarawat Hypermarket
Sources: en.wikipedia.org
== Chemistry == Edrophonium, ethyl-(3-hydroxyphenyl)dimethylammonium chloride, is made by reacting 3-dimethylaminophenol with ethyl bromide, which forms ethyl(3-hydroxyphenyl)dimethylammonium bromide, the bromine atom of which is replaced with a chlorine atom by reacting it with silver chloride, giving edrophonium.
ALK-positive ALCL is diagnosed by histological and immunological examinations of involved tissues, typically lymph nodes. These tissues have lymphoma-like infiltrates that have variable numbers of ALCL "hallmark" cells, i.e. cells with kidney- or horseshoe-shaped nuclei that strongly express CD30 as detected by immunohistochemistry and an ALK fusion protein as detected by fluorescence in situ hybridization. These cells are scattered throughout the infiltrates. WHO classifies these infiltrates into 5 patterns: a common pattern consisting of large variably shaped cells with large nuclei that typically contain multiple nucleoli (60–70% of cases); a small-cell pattern consisting of small to medium-sized neoplastic cells with clear cytoplasm and "hallmark" cells that are concentrated around small blood vessels (5–10% of cases); a lymphohistiocytic pattern consisting of small neoplastic cells along with abundant histiocytes (10% of cases); a Hodgkin's-like pattern in which the architecture resembles the nodular sclerosis pattern of Hodgkin lymphoma (3% of cases); and a composite pattern consisting of two or more of the just described patterns (15% of cases). Detection of circulating autoantibody against ALK supports the diagnosis. Individuals with low levels of these autoantibodies are at an increase risk of relapsing after treatment.
A composite cross population (CCP) is created by crossing a number of plants from different lines, and subsequently bulking seeds from the resulting offspring. This makes a CCP a population of plants with a lot of inherent genetic diversity, in contrast to monocultures where all plants are clones and homozygous at all loci (fully inbred). In recent years CCPs have been proposed as a way to create modern landraces of wheat, barley and oats. Research is done to explore whether they are better suited for organic farming than the modern cultivars. They are suited for participatory breeding of crops, which is in contrast to cultivars owned by big breeding companies. The idea of using CCPs in plant breeding was published in 1956 based on the barley composite cross devised by Harry Harlan and Mary Martini in 1929. Yield data for 4 different populations for 8–28 years were presented in the article and after 8–15 years of repeated breeding under natural selection, the populations out-yielded the reference cultivar.
Lutetium's compounds almost always contain the element in the +3 oxidation state. Aqueous solutions of most lutetium salts are colorless and form white crystalline solids upon drying, with the common exception of the iodide, which is brown. The soluble salts, such as nitrate, sulfate and acetate form hydrates upon crystallization. The oxide, hydroxide, fluoride, carbonate, phosphate and oxalate are insoluble in water. Lutetium metal is slightly unstable in air at standard conditions, but it burns readily at 150 °C to form lutetium oxide. The resulting compound is known to absorb water and carbon dioxide, and it may be used to remove vapors of these compounds from closed atmospheres. Similar observations are made during reaction between lutetium and water (slow when cold and fast when hot); lutetium hydroxide is formed in the reaction. Lutetium metal is known to react with the four lightest halogens to form trihalides; except the fluoride they are soluble in water. Lutetium dissolves readily in weak acids and dilute sulfuric acid to form solutions containing the colorless lutetium ions, which are coordinated by between seven and nine water molecules, the average being [Lu(H2O)8.2]3+.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.